Core Insights - Zhonghui Biotech-B (02627) reported a revenue of RMB 71.123 million for the six months ending June 30, 2025, representing a year-on-year growth of 919.25% [1] - The company focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies [1] - Zhonghui Biotech has two core products: a quadrivalent influenza virus subunit vaccine and an investigational freeze-dried human rabies vaccine, along with 11 other vaccines in development [1] Company Overview - Established in 2015, Zhonghui Biotech is headquartered in China and aims to meet domestic demand while adhering to global standards for its vaccine products [1] - All vaccine products and those in development are classified as second-class vaccines in China [1] Research and Development Capabilities - The company has established three comprehensive vaccine development support platforms: a gene engineering and protein expression and purification platform, an mRNA vaccine research platform, and an adjuvant development and production platform [1] - Zhonghui Biotech utilizes proprietary technology platforms, including large-scale amplification, polysaccharide conjugation technology, and microbiology and immunology research platforms, to enhance its R&D capabilities [1]
一图读懂中慧生物-B(02627)2025年中期业绩